Overview

An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes

Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
This is an open label, observational study designed to collect data that characterize the use of SYMLIN following the introduction of the medication into the marketplace. Health care providers and subjects selected for study participation are intended to be representative of those providers prescribing, and subjects receiving, SYMLIN therapy.
Details
Lead Sponsor:
AstraZeneca
Treatments:
Islet Amyloid Polypeptide
Pramlintide